

Remarks

Upon entry of the foregoing amendment, claims 41-92 are pending in the application, with claim 41 being the independent claim. Claims 1-40 are sought to be cancelled without prejudice to or disclaimer of the subject matter therein. New claims 41-92 are sought to be added. New claims 41-92 correspond to the invention of Group I as provisionally elected in Applicants' Reply to Restriction Requirement filed herewith. Applicants have also amended the specification to perfect the priority claim. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Support for the new claims can be found throughout the specification. For the Examiner's convenience, **Table 2** (attached) sets out examples of locations where support for the new claims can be found in the present application.

Applicants also provide the following in **Table 1**: a list of each peptide recited in the claims, the peptide number, the identity of the HER2/neu antigen where the peptide is found, and the filing date and serial number of the application in which the peptide was first disclosed by Applicants.

Conclusion

Prompt and favorable consideration of this Preliminary Amendment is respectfully requested. Applicants believe the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: 9/2/03

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

Table 1- Claimed Peptides

Peptide	SEQ ID NO	Antigen	Earliest Priority Application Where Peptide Is Disclosed	Filing Date
KVFGSLAFV	4233	HER2/neu.369.V2V9	60/141,422	6/29/99
VVI.GVVFGV	4239	HER2/neu.665.V2V9	60/141,422	6/29/99

Table 2- Examples of Support for Claims

<u>Claim Language</u>	<u>Support in This Application</u>	<u>Support in Priority Appl. No. 60/141,422</u>
T helper peptide	p. 50, lines 17-19 and 29-32; p. 51, lines 1-2	p. 16, line 19 through p. 17, line 5
Spacer	p. 50, lines 20-27	p. 16, lines 24 through p. 17, line 2
Carrier	p. 42, lines 26-27; p. 43, lines 1-4	p. 20, lines 9-12
Lipid	p. 51, line 30 through p. 52, line 11	p. 17, lines 8-16
Fusion protein	p. 53, lines 33-34	p. 18, lines 16-17
Liposome	p. 51, line 33 through p. 52, line 3; p. 55 line 33 through p. 56, line 15	p. 17, lines 11-13; p. 23, lines 3-19
Pharmaceutically acceptable carrier	p. 55, lines 27-32	p. 22, lines 14-19
Linker amino acids	p. 52, lines 14-19	p. 17, lines 26-29
Homopolymer/heteropolymer	p. 42, lines 26-28	p. 20, lines 3-5
Universal T helper cell epitope	p. 43, lines 22-25 p. 51, lines 12-20	p. 20, lines 30-32
Different peptides	p. 42, lines 28-32	p. 20, lines 4-8
8, 9, 10, or 11 amino acids in length	p. 12, lines 32-34	p. 5, lines 1-3